Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Plasmablastic Lymphoma × belantamab mafodotin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 12 Recurrence 2 Immunoglobulin Light-chain Amyloidosis 2 Plasmablastic Lymphoma 1 Neoplasms, Plasma Cell 1 Amyloidosis 1

Interventions

varlilumab 1 belantamab mafodotin 1 Vincristine 1 Rituximab 1 Prednisone 1 Nivolumab 1 Immunoglobulin G 1 Etoposide 1 Doxorubicin 1 Disulfides 1 Cyclophosphamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04676360 2026-03-13

Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma

Massachusetts General Hospital

Phase 2 Terminated

10 enrolled 11 charts

Plasmablastic Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡